---
title: "Pyridostigmine - Myasthenia Gravis"
sidebar: mydoc_sidebar
permalink: db00545-mesh-d009157-1.html
toc: false 
---


Path ID: `DB00545_MESH_D009157_1`
{% include image.html url="images/db00545-mesh-d009157-1.png" file="db00545-mesh-d009157-1.png" alt="db00545-mesh-d009157-1" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| MESH:D011729 | pyridostigmine | Drug |
| UniProt:P22303 | Acetylcholinesterase | Protein |
| GO:0001507 | acetylcholine catabolic process in synaptic cleft | BiologicalProcess |
| HP:0011804 | Abnormal muscle physiology | PhenotypicFeature |
| MESH:D009157 | Myasthenia gravis | Disease |
|------------|------|---------|

## Relationships

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Pyridostigmine | NEGATIVELY REGULATES | Acetylcholinesterase |
| Acetylcholinesterase | POSITIVELY REGULATES | Acetylcholine Catabolic Process In Synaptic Cleft |
| Acetylcholine Catabolic Process In Synaptic Cleft | AFFECTS RISK FOR | Abnormal Muscle Physiology |
| Abnormal Muscle Physiology | MANIFESTATION OF | Myasthenia Gravis |
|---------|-----------|---------|

Reference: 
  - [https://go.drugbank.com/drugs/DB00545#BE0000426](https://go.drugbank.com/drugs/DB00545#BE0000426)
  - [https://en.wikipedia.org/wiki/Pyridostigmine#Mechanism_of_action](https://en.wikipedia.org/wiki/Pyridostigmine#Mechanism_of_action)
  - [https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1115/](https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1115/)
